Cytomegalovirus (CMV) continues to be one of the most common infections after solid-organ
transplantation, resulting in significant morbidity, graft loss, and adverse outcomes …

Cytomegalovirus (CMV) infection is a common complication after liver transplantation, and it
is associated with multiple direct and indirect effects. Management of CMV infection and …

We systematically reviewed and meta-analyze the efficacy of universal prophylaxis (UP) and
preemptive (PE) strategies (using ganciclovir or valganciclovir) in preventing …

Liver transplantation recipients (LTRs) who are seropositive for cytomegalovirus
(CMV)(recipient seropositive [R+]) are at intermediate risk for CMV disease. A preventative …

Background Cytomegalovirus (CMV) is a common opportunistic infection in patients after
liver transplant (LT). Guidelines recommend 900 mg daily of valganciclovir; however …

Delayed‐onset cytomegalovirus (CMV) disease can occur among liver transplant recipients
after CMV prophylaxis is stopped. We hypothesized that delayed‐onset CMV disease (> 100 …

Human Cytomegalovirus (HCMV) is found ubiquitously in humans worldwide, and once
acquired, the infection persists within the host throughout their life. Although …

Dr. Barth serves as the Director of Liver Transplantation and Associate Director of The
University of Chicago Medicine Transplant Institute. His clinical practice focuses on kidney …

Spotlight on Impactful Research: Lowâ•’Dose Valganciclovir for Cytomegalovirus Prophylaxis
in Intermediateâ•’Risk Live Page 1 53 | CliniCal liver Disease, vOl 17, nO 2, FeBrUarY 2021 …

Introduction Liver transplantation is a standardized treatment for the management of chronic
liver failure, as well as, in selected cases of unresectable tumors and acute liver failure …